BC Week In Review | Sep 2, 2013
Company News

Altus Formulation Inc., Paladin deal

Paladin disclosed in its 2Q13 earnings that it holds a 35% equity stake in Altus and also has an option to in-license and receive royalties on products developed and commercialized by Altus. Former employees of...
BC Week In Review | May 20, 2013
Company News

Altus Formulation, Halo Pharmaceutical Inc. deal

Drug development and commercial manufacturing services company Halo acquired an undisclosed minority stake in drug formulation company Altus. The companies also partnered to allow Halo to provide its clients with Altus' technology and services, which...
BC Week In Review | Apr 22, 2013
Company News

Lantheus management update

Lantheus Medical Imaging Inc. , North Billerica, Mass.   Business: Diagnostic   Hired: Mary Anne Heino as chief commercial officer, formerly president at Angelini Labopharm LLC; she replaces Cyrille Villeneuve, who will become international VP  ...
BC Week In Review | Apr 15, 2013
Company News

Labopharm, Laboratoires du Dr. E. Bouchara deal

DDS and Bouchara will develop an oral controlled-release formulation of a currently marketed drug using DDS's Contramid technology. The partners plan pilot clinical studies in early 1998. Labopharm Inc. (TSE:DDS), Montreal, Quebec   Laboratoires du...
BC Week In Review | Oct 17, 2011
Company News

Labopharm, Paladin deal

Paladin completed its acquisition of Labopharm for C$0.29 per share in cash or C$20.4 million ($19.5 million) based on 71.6 million shares outstanding at Aug. 2 (see BioCentury, Aug. 22). Labopharm Inc. , Laval, Quebec  ...
BC Week In Review | Aug 29, 2011
Company News

Labopharm, Angelini deal

In July, companies said they would terminate their JV, Angelini Labopharm LLC, and Labopharm would transfer its 50% stake in the JV to Angelini. The JV was formed in May 2010 to market major depressive...
BC Week In Review | Aug 22, 2011
Company News

Labopharm, Paladin deal

Paladin will acquire Labopharm for C$0.29 per share in cash, or C$20.4 million ($20.7 million) based on 71.6 million shares outstanding at Aug. 2. The price is a 68% premium to Labopharm's close of C$0.17...
BioCentury | Aug 22, 2011
Analyst Picks & Changes

Analyst Picks & Changes

Analyst Picks & Changes Company Bank Analyst Coverage Opinion Wk chg 8/19 cls Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) Piper Jaffray Edward Tenthoff Upgrade Overweight (from neutral) -4% $6.62 Tenthoff also raised his target to $12 from...
BC Week In Review | Jul 4, 2011
Company News

Labopharm, Angelini neurology, drug delivery news

Labopharm said its JV with Angelini, Angelini Labopharm, reduced its U.S. sales force for major depressive disorder (MDD) drug Oleptro trazodone by 65 (50%) to 65 to reduce costs. The reduction is expected to save...
BC Week In Review | Jun 27, 2011
Financial News

Labopharm financial update

Labopharm said it will voluntarily delist its shares from NASDAQ effective June 30. The company will continue to trade on the Toronto Stock Exchange. Labopharm said it does not anticipate it will be able to...
Items per page:
1 - 10 of 256
BC Week In Review | Sep 2, 2013
Company News

Altus Formulation Inc., Paladin deal

Paladin disclosed in its 2Q13 earnings that it holds a 35% equity stake in Altus and also has an option to in-license and receive royalties on products developed and commercialized by Altus. Former employees of...
BC Week In Review | May 20, 2013
Company News

Altus Formulation, Halo Pharmaceutical Inc. deal

Drug development and commercial manufacturing services company Halo acquired an undisclosed minority stake in drug formulation company Altus. The companies also partnered to allow Halo to provide its clients with Altus' technology and services, which...
BC Week In Review | Apr 22, 2013
Company News

Lantheus management update

Lantheus Medical Imaging Inc. , North Billerica, Mass.   Business: Diagnostic   Hired: Mary Anne Heino as chief commercial officer, formerly president at Angelini Labopharm LLC; she replaces Cyrille Villeneuve, who will become international VP  ...
BC Week In Review | Apr 15, 2013
Company News

Labopharm, Laboratoires du Dr. E. Bouchara deal

DDS and Bouchara will develop an oral controlled-release formulation of a currently marketed drug using DDS's Contramid technology. The partners plan pilot clinical studies in early 1998. Labopharm Inc. (TSE:DDS), Montreal, Quebec   Laboratoires du...
BC Week In Review | Oct 17, 2011
Company News

Labopharm, Paladin deal

Paladin completed its acquisition of Labopharm for C$0.29 per share in cash or C$20.4 million ($19.5 million) based on 71.6 million shares outstanding at Aug. 2 (see BioCentury, Aug. 22). Labopharm Inc. , Laval, Quebec  ...
BC Week In Review | Aug 29, 2011
Company News

Labopharm, Angelini deal

In July, companies said they would terminate their JV, Angelini Labopharm LLC, and Labopharm would transfer its 50% stake in the JV to Angelini. The JV was formed in May 2010 to market major depressive...
BC Week In Review | Aug 22, 2011
Company News

Labopharm, Paladin deal

Paladin will acquire Labopharm for C$0.29 per share in cash, or C$20.4 million ($20.7 million) based on 71.6 million shares outstanding at Aug. 2. The price is a 68% premium to Labopharm's close of C$0.17...
BioCentury | Aug 22, 2011
Analyst Picks & Changes

Analyst Picks & Changes

Analyst Picks & Changes Company Bank Analyst Coverage Opinion Wk chg 8/19 cls Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) Piper Jaffray Edward Tenthoff Upgrade Overweight (from neutral) -4% $6.62 Tenthoff also raised his target to $12 from...
BC Week In Review | Jul 4, 2011
Company News

Labopharm, Angelini neurology, drug delivery news

Labopharm said its JV with Angelini, Angelini Labopharm, reduced its U.S. sales force for major depressive disorder (MDD) drug Oleptro trazodone by 65 (50%) to 65 to reduce costs. The reduction is expected to save...
BC Week In Review | Jun 27, 2011
Financial News

Labopharm financial update

Labopharm said it will voluntarily delist its shares from NASDAQ effective June 30. The company will continue to trade on the Toronto Stock Exchange. Labopharm said it does not anticipate it will be able to...
Items per page:
1 - 10 of 256